Yüklüyor......

Extended treatment with single-agent ibrutinib at the 420 mg dose leads to durable responses in chronic lymphocytic leukemia/small lymphocytic lymphoma

PURPOSE: Ibrutinib, a first-in-class, once-daily, oral inhibitor of Bruton’s tyrosine kinase, promotes apoptosis, and inhibits B-cell proliferation, adhesion, and migration. Ibrutinib has demonstrated single-agent efficacy and acceptable tolerability at doses of 420 and 840 mg in patients with chron...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Cancer Res
Asıl Yazarlar: Coutré, Steven E., Furman, Richard R, Flinn, Ian W., Burger, Jan A., Blum, Kristie, Sharman, Jeff, Jones, Jeffrey, Wierda, William, Zhao, Weiqiang, Heerema, Nyla A., Johnson, Amy J., Tran, Anh, Zhou, Cathy, Bilotti, Elizabeth, James, Danelle F., Byrd, John C., O’Brien, Susan
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2017
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6317338/
https://ncbi.nlm.nih.gov/pubmed/28073846
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-1431
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!